Immunotherapy Research Antibodies
Absolute Antibody has harnessed recombinant antibody technology to develop a comprehensive collection of engineered recombinant antibodies.
Place your order directly with the manufacturer.
These antibodies specifically target clinically relevant proteins, including mouse homologs of current therapeutic targets that have been engineered for optimal in vivo performance, as well as bispecific antibodies, providing researchers with cutting-edge tools to propel cancer immunotherapy research forward.
Tools available to empower cancer immunotherapy research include:
- VivopureX™ Antibodies: These recombinant antibodies are engineered for improved in vivo performance in live mouse models, with Fc silencing and isotype switching for tailored therapeutic effects, and matched antibody species for reduced immunogenicity and longer serum half-life.
- Research-Grade Biosimilars: Absolute Antibody offers research-grade biosimilars to grant access to research tools for the study and evaluation of biological processes without the need to source and purchase costly therapeutic-grade biologics. The immunotherapy antibodies are engineered from the original human species into mouse, rabbit, rhesus monkey, and cynomolgus monkey formats for added research potential.
- Bispecific Antibodies: Engage two distinct targets with one antibody reagent with the range of recombinant engineered murine bispecific antibodies. The collection offers high purity, low immunogenicity, and tailored effector function for in vivo applications in mouse models. Absolute Antibody antibody engineers can also custom engineer any bispecific antibody you can imagine.
- Tumor Marker Antigens: Antibodies that target tumor markers can enhance cancer treatment and diagnosis. Benefit from the selection of recombinant engineered tumor marker antibodies, with 100% biological definition, Fc Silent™ formats for eliminated ADCC, and a variety of species and isotypes available to better address your research needs.
Bispecific ADCs targeting the cancer, not the patient
Tuesday, July 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Bispecific antibody-drug conjugates (ADCs) represent an emerging frontier in targeted cancer therapy, combining the precision of antibody-based targeting with the potency of cytotoxic payloads. By recognizing two distinct tumor-associated markers rather than one, bispecific ADCs can improve tumor selectivity, helping to distinguish cancer cells from healthy tissue and potentially reducing off-target effects. As the field advances, researchers are exploring innovative approaches to address longstanding challenges in efficacy, safety, and patient outcomes, making bispecific ADCs a rapidly growing area of interest in oncology research and drug development.
This SelectScience webinar introduces BiVictriX Therapeutics and its role as an early pioneer in bispecific, logic gated, ADCs. It will cover how ADCs are reshaping targeted cancer therapy and why bispecific targeting offers a route to improved tumor selectivity and reduced off-tumor toxicity. The presentation will also explore the key steps to take when designing a bispecific ADC, including target selection, antibody format, linker strategy, and payload choice, and how these decisions influence efficacy, safety, and clinical potential.
